BOFAS 2023 Video Recap BOFAS 2023 Video Recap Now Live for Members who attended the conference 19 May 2023 If you are a BOFAS member who attended the 2023 annual congress, you can now access the full video recap of the conference here. Read more
BOFAS 2024 - Belfast BOFAS 2024 - Belfast 6th to 8th March 2024 15 March 2023 BOFAS 2024 will be held in Belfast from 6th to 8th of March Read more
Website Updates Website Updates Research Grants and Email Patient Info Leaflets 31 March 2022 The research grants page has been updated and a list of previous grants can now be viewed. Patient information pages now have a link so that the page link can be shared with patients via email. Read more
2Oct2025 BOFAS Principles Course - Dubai 02/10/2025 - 04/10/2025 Read more The aim is to give Overseas Trainee Orthopaedic Surgeons a solid grounding in the principles and the decision making in Foot & Ankle Surgery. There is an emphasis on clinical examination of cases, small group discussions and learning surgical approaches in the cadaver lab. This is the first course BOFAS is running in UAE and the aim is to expand the Foot and Ankle education and training in the Middle East and Gulf area. Venue - Le Meridien, Dubai, United Arab Emirates Documents to download ACv3BOFAS-Principles-Course-Programme-DXB(.pdf, 2.13 MB) - 478 download(s) Read more
20Oct2025 BOFAS Principles Course Taunton 20/10/2025 - 21/10/2025 Read more These courses are aimed at Higher Surgical Trainees / ST3 onwards and are designed to teach the core of Foot and Ankle surgery in an informal and interactive environment. The emphasis is on clinical examination cases, discussion groups and typical day-to-day clinic scenarios. Although not an exam preparation course, content is taught to the standard expected in the FRCS(Tr & Orth) exam; that of a day-one non-specialist orthopaedic consultant. Applications will open on 1st September 2023. Venue - Taunton (TBC) Documents to download BOFAS-Course-Programme--Taunton-2025(.docx, 31.88 KB) - 741 download(s) Read more
Togay Koç / 07 September 2022 / Categories: Abstracts, 2019, Podium Cartiva synthetic cartilage implant hemiarthroplasty for treatment of hallux rigidus B. Brandao, A. Aljawadi, A. Fox, A. Pillai Objectives: Cartiva synthetic cartilage implant (SCI) is licenced for use in management of symptomatic hallux rigidus in several countries including the UK. As for now, there are no independent comparative series for treatment of hallux rigidus utilising polyvinyl alcohol implants. Study design and methods: Patients at a single centre with symptomatic hallux rigidus who underwent Cartiva SCI implant procedure were identified. First metatarsophalangeal joint arthritis was radiographically graded according to the Hattrup and Johnson (HJ) classification. Pre-operative and post-operative patient-reported outcomes were evaluated using the Foot and Ankle Ability Measure (FAAM) activities of daily living subscale and the Manchester-Oxford Foot Questionnaire (MOXFQ). Results: 66 patients (19M, 47F) (43R and 23L) were followed up for an average of 14 months (min=2, max=36). 17 patients suffered from HJ2/moderate arthritis and 49 patients with grade HJ3/severe arthritis. Post-operative mean FAAM scores showed statistically significant improvement (p< 0.0001). Patients reported a 40% increase in functionality during activities of daily living. All 3 MOXFQ Domain scores improved significantly (p< 0.02). The Index score improved by 28 points (p< 0.0001). There was no correlation between length of follow up or age and PROMs (r=0.129). No statistical difference was demonstrated between sexes. However clinically, males and older patients exhibit better outcomes. There was a 89.4% patient satisfaction with the use of Cartiva. Conclusions: Our study shows excellent results with statistically significant improvements in functional outcomes, and promising short-term follow-up with low early revision rates. Pain in particular was significantly reduced. One third of patients developed post-operative stiffness requiring a manipulation under anaesthesia. Patient selection is key. Additional imaging may be required to assess sesamoid osteoarthritis. At 3 years the implant has demonstrated to be safe and efficacious in the management of hallux rigidus. Durability and survivability of the implant will continue to be studied in this cohort. Print 931 Tags: Hallux Rigidus